Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCQB - Delayed Quote USD

Centogene N.V. (CNTGF)

0.1800

+0.0300

+(20.00%)

At close: April 4 at 4:00:00 PM EDT

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”) today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited (“Charme”). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE’s sole operating subsidiary, certain intercompany rece

GlobeNewswire 25 days ago

CNTGF
+20.00%
CENTOGENE Announces Voting Results of Extraordinary General Meeting

Approval of All Resolutions, Including Announced Transaction With Charme Capital PartnersCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the prev

GlobeNewswire 3 months ago

CNTGF
+20.00%
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement (“SPA”) pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited (“Charme”), a pan-European pri

GlobeNewswire 4 months ago

CNTGF
+20.00%
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Parkinson's patients than in the general population CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the essential life science partner for data-driven answers i

GlobeNewswire 6 months ago

CNTGF
+20.00%
CNTG
0.00%

Performance Overview

Return	CNTGF	S&P 500 (^GSPC)
YTD	+32.35%	-13.73%
1-Year	-74.65%	-1.42%
3-Year	-95.76%	+10.72%

Try again.